It has been reported that SOX2OT inhibition can restrict the bladder cancer stem cell (CD44+, ALDH1+) self-renewal and cisplatin resistance by SOX2 regulation [28]. This evidence concerns the gene SOX2-OT and urinary bladder cancer.